Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Clarient to Offer BioMerieux's BRAF CDx

Premium

BioMérieux and Clarient, a GE Healthcare company, said this week that BioMérieux's molecular diagnostic test THxID-BRAF has been added to Clarient's service offerings.

The THxID-BRAF test is a real-time PCR-based companion diagnostic assay developed by BioMérieux, intended as an aid to oncologists in selecting melanoma patients who could benefit from treatments for their tumors that carry the BRAF V600E and V600K mutations. The assay received pre-market approval from the US Food and Drug Administration for commercialization in the US in May 2013.

Clarient will use THxID BRAF to aid oncologists in selecting metastatic melanoma patients whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline's Tafinlar (dabrafenib), as well as in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for possible treatment with Mekinist (trametinib).

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.